Shares of Prime Medicine ( PRME 13.07%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam Therapeutics.

Learn more about whether Kymera Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's ...

Analysts' ratings for VYNE Therapeutics VYNE over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table provides a quick overview of their recent ratings ...

Stifel lowered the firm’s price target on Fate Therapeutics (FATE) to $3 from $5 and keeps a Hold rating on the shares. Key updates the firm will be tracking throughout 2025 include FT819 data ...

Wells Fargo lowered the firm’s price target on Fate Therapeutics (FATE) to $4 from $5 and keeps an Equal Weight rating on the shares. The firm continues to think Fate’s main opportunity is in ...

Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline. The big pharma swooped in after the California biotech reported ...

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report)’s stock price traded up 5.2% during mid-day trading on Tuesday following a stronger than expected earnings report.The company traded as ...

A review of the scientific literature suggests the potential of caspase-4/5 as targets for a broad range of inflammatory diseases, including inflammatory bowel disease, hidradenitis suppurativa, and ...

Pamela Anderson Set to Join Ellen Burstyn and Taika Waititi in Kornél Mundruczó’s New Drama Place to Be; Find More Bollywood Newswrap, March 17: FIR filed against Orry and others near Vaishno ...